Surviving Melanoma in Europe.
Access to prevention, early detection and effective treatment for all.
joint M-icab/ ESO conference
Recent unprecedented progress in melanoma therapies provide for the first time hope for patients in advanced stages of the disease. However, navigating a fast-evolving treatment landscape presents a real challenge, not only for patients but also their advocates.
With novel treatments in development, the most promising agents are often only accessible in a clinical trial setting. For this reason, access to and participation in clinical studies strongly shape the reality for stage 4 and increasingly, also stage 3 melanoma patients.
The current logistical, ethical and humane challenges to melanoma patients’ enrolment in clinical trials now appeal for a change of paradigm in the design and conduct of these trials.
The topic of this conference is therefore patient-centred clinical trial design in Melanoma and the different stakeholders (patients, clinicians, regulators, HTA and industry) will contribute their perspectives to whether alternative licensing models- such as adaptive licensing- are better suited to address the needs of Melanoma patients.
The focus of the second day of the conference is Melanoma patient advocacy in Europe and how we as advocates can make use of the newly founded Melanoma Patient Network Europe to exchange know-how and collaborate effectively on European issues in Melanoma.
There will be plenty of opportunity for patient advocates to meet, including a poster session for advocacy organisations to present themselves and their most successful advocacy projects!
We are looking forward to meeting you in Brussels!
Bettina Ryll, Conference Chair
Melanoma Patient Network Europe